source
- FDA approves Hibsago, first antisense therapy for chronic hepatitis BThe U.S. Food and Drug Administration has approved Hibsago (bepirovirsen) injection to be used alongside existing antiviral therapy for chronic hepatitis B virus infection in certain adults without…
- Biopharma Sentiment Index climbs to upbeat 105 in Q3 2026, marking strongest optimism in yearsEndpoints Signal released its Q3 2026 Biopharma Sentiment Index, showing a dramatic lift in industry mood. The survey indicates the sector is finally in a positive territory after a four-year downt…